CLEARWATER, Fla., June 7, 2017 /PRNewswire/ -- Today, CoreRx and Aimmune Therapeutics announced their expansion of Myerlake-3. CoreRx is a contract development and manufacturing organization (CDMO) servicing the pharmaceutical and biotechnology industries, and Aimmune is a clinical-stage biopharmaceutical company advancing a therapeutic approach for the treatment of peanut and other food allergies. Jointly, the companies have increased manufacturing operations at CoreRx's ICOT Center campus in Clearwater, Florida.
This new expansion consists of approximately 20,000 square feet of manufacturing and warehouse space at CoreRx's 5733 Myerlake Circle (ML-3) location.
This growth will necessitate additional staffing at CoreRx including positions within pharmaceutical development, manufacturing, engineering, quality assurance and packaging. "The Tampa Bay area is a great place to expand the base of scientific capabilities. These expansions in the Private-sector result in high-paying, skilled roles that contribute immensely to society by providing products and services that impact the quality of lives of Americans. These expansions continue to showcase the Tampa regions expertise in high technology manufacturing on a national and global level." said Todd R. Daviau, President and CEO of CoreRx. "And, we will continue to expand our capabilities to meet the growing demands of our clients."
About CoreRx
CoreRx® is a CDMO with a focus on oral and topical delivery of drug products, offering state of the art facilities to support your supply chain needs throughout the entire clinical trial process. Our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid, and semi-solid dosage forms.
The art of drug product development is the core of what we do. We differentiate ourselves by mixing highly experienced scientists with a wide range of technologies, to deliver optimal solutions to meet our clients' needs. From simple formulations to complex, delayed or targeted release dosage forms, CoreRx's solutions maximize client investments, shorten development time and reduce overall costs.
Contact:
Michelle Hall, Marketing Director
(727) 259-6950
[email protected]
SOURCE CoreRx
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article